Assessing Tumour Localized 4-1BB Stimulation for Cancer Immunotherapy
Time: 9:30 am
day: Day One
Details:
- Overcoming 1st generation 4-1BB agonist safety and efficacy drawbacks with a 4-1BB/PD-L1 bispecific Anticalin® protein/mAb fusion protein
- Harnessing 4-1BB localized activity in the TME, while also offering the benefit of checkpoint inhibition
- Preclinical data package to guide clinical study
